Hospice & Palliative Care EBITDA Valuation Multiples
Medicare-certified hospice agencies with clean compliance records and stable census trade at 4x–7x EBITDA. Here's what moves the needle in lower middle market transactions.
Hospice and palliative care businesses in the $1M–$5M revenue range typically sell at 4x–7x EBITDA, driven by Medicare certification status, average daily census trends, referral source diversification, and compliance history. Private equity roll-up platforms and regional strategic acquirers dominate deal activity, and multiples are sensitive to OIG exposure, staff stability, and Medicare cap position. Clean operators with tenured clinical teams and diversified referral networks command premium valuations.
Hospice & Palliative Care EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or Compliance-Impaired | $300K–$600K | 3x–4x | Active Medicare audits, RAC findings, high staff turnover, or referral concentration above 30% from a single source. Buyers price in significant remediation and compliance risk. |
| Average Operator | $400K–$800K | 4x–5x | Stable ADC, acceptable compliance record, moderate referral diversification, but limited accreditation, below-average length-of-stay metrics, or owner-dependent referral relationships. |
| Strong Independent Agency | $600K–$1.2M | 5x–6x | Growing ADC, clean survey history, diversified referral network, tenured clinical leadership, ACHC or CHAP accreditation, and well-documented financials with normalized EBITDA. |
| Premium Platform-Ready Asset | $900K–$1.5M | 6x–7x | Scalable operations, multi-site or multi-county footprint, favorable CON-free state, strong payer mix, zero active compliance issues, and management team willing to roll equity. |
What Drives Hospice & Palliative Care Multiples
Medicare Cap Position
High impactAgencies near or exceeding the Medicare annual per-beneficiary cap face revenue ceilings and billing scrutiny. Buyers heavily discount or restructure deals around unresolved cap exposure.
Average Daily Census Trends
High impactA growing or stable ADC of 40–150 patients signals operational health. Declining ADC raises census volatility concerns and compresses buyer confidence in forward EBITDA projections.
Referral Source Diversification
High impactNo single referral source exceeding 20% of admissions is a key buyer criterion. Over-concentration in one hospital, SNF, or physician creates post-acquisition revenue risk.
Clinical Staff Stability
Medium-High impactTenured RNs, a stable Director of Nursing, and low contracted-staff ratios increase buyer confidence. High turnover or unfilled clinical positions signal operational fragility and integration risk.
Compliance and Survey History
High impactClean CMS surveys, no OIG enforcement actions, and documented anti-kickback safe harbors for referral relationships materially expand the buyer pool and support premium multiples.
Recent Market Trends
PE-backed hospice roll-up activity accelerated through 2022–2024 as platforms compete for Medicare-certified agencies in non-CON states. Buyers are increasingly scrutinizing Medicare eligibility documentation following heightened OIG enforcement. Staffing cost inflation has compressed EBITDA margins, making normalized add-backs a central negotiation point. SBA 7(a) financing remains viable for owner-operator buyers targeting sub-$3M revenue agencies with clean compliance records.
Sample Hospice & Palliative Care Transactions
Medicare-certified independent hospice in Southeast, ADC of 65, clean survey history, diversified SNF and physician referral base, retiring founder-operator
$550K
EBITDA
5.5x
Multiple
$3.0M
Price
Midwest hospice agency, ADC of 110, CHAP-accredited, multi-county service area, tenured clinical team, PE platform add-on acquisition with equity rollover
$1.1M
EBITDA
6.5x
Multiple
$7.2M
Price
Small urban hospice, ADC of 38, single referral source at 35% of admissions, pending RAC audit review, buyer negotiated compliance escrow holdback
$380K
EBITDA
3.8x
Multiple
$1.4M
Price
EBITDA Valuation Estimator
Get your Hospice & Palliative Care business value range instantly
Industry: Hospice & Palliative Care · Multiples based on 4x–5x (Average Operator)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect when selling my hospice agency?
Most Medicare-certified hospice agencies in the $1M–$5M revenue range sell at 4x–7x EBITDA. Clean compliance records, growing ADC, and diversified referrals drive multiples toward the upper end.
How does Medicare cap exposure affect my hospice company's valuation?
Active or approaching cap exposure is a significant deal risk. Buyers will discount valuation, require escrow holdbacks, or restructure as earnouts until cap liability is resolved or quantified.
Do hospice acquisitions qualify for SBA financing?
Yes. Medicare-certified hospice agencies with clean financials and no active compliance investigations are generally SBA 7(a) eligible. Lenders scrutinize Medicare reimbursement history and payer mix carefully.
What deal structure is most common in hospice acquisitions?
Asset purchases with Medicare provider agreement novation are most common. Deals typically include a 10–20% seller note or earnout tied to census retention, with escrow holdbacks for compliance contingencies.
More Hospice & Palliative Care Guides
Find Hospice & Palliative Care businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required